Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 5 | 2014 | 103 | 0.610 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2016 | 1 | 0.480 |
Why?
|
| Hepatocytes | 1 | 2016 | 2 | 0.480 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 10 | 0.480 |
Why?
|
| Dendritic Cells | 3 | 2014 | 4 | 0.430 |
Why?
|
| Anti-Retroviral Agents | 2 | 2014 | 5 | 0.370 |
Why?
|
| Receptors, Chemokine | 2 | 2007 | 4 | 0.280 |
Why?
|
| Interleukins | 2 | 2015 | 6 | 0.220 |
Why?
|
| Viral Load | 3 | 2014 | 14 | 0.190 |
Why?
|
| Cells, Cultured | 2 | 2016 | 119 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2014 | 13 | 0.140 |
Why?
|
| Humans | 8 | 2015 | 2957 | 0.130 |
Why?
|
| Female | 7 | 2015 | 1724 | 0.130 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 1 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 1 | 0.120 |
Why?
|
| Microscopy, Atomic Force | 1 | 2016 | 2 | 0.120 |
Why?
|
| Cytoskeleton | 1 | 2016 | 6 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 5 | 0.120 |
Why?
|
| Adult | 6 | 2015 | 794 | 0.120 |
Why?
|
| Animals | 2 | 2016 | 1050 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 45 | 0.120 |
Why?
|
| Herpes Genitalis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Herpes Labialis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 88 | 0.120 |
Why?
|
| Genotype | 1 | 2015 | 85 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2014 | 13 | 0.110 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2015 | 2 | 0.110 |
Why?
|
| Surface-Active Agents | 1 | 2015 | 3 | 0.110 |
Why?
|
| Peripheral Nerves | 1 | 2015 | 2 | 0.110 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 2 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 16 | 0.110 |
Why?
|
| Peptides | 1 | 2015 | 19 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 1 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 6 | 0.110 |
Why?
|
| Vagina | 1 | 2014 | 2 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2014 | 7 | 0.100 |
Why?
|
| Plasma | 1 | 2014 | 5 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 1 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 1 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 4 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 30 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 1 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2013 | 4 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 92 | 0.100 |
Why?
|
| Cytokines | 1 | 2011 | 33 | 0.090 |
Why?
|
| Inflammation | 1 | 2011 | 31 | 0.090 |
Why?
|
| HIV-1 | 1 | 2011 | 59 | 0.080 |
Why?
|
| Biomarkers | 1 | 2011 | 101 | 0.080 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 2 | 0.080 |
Why?
|
| Receptors, CCR7 | 2 | 2007 | 4 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2007 | 23 | 0.080 |
Why?
|
| Imidazoles | 2 | 2007 | 17 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2015 | 203 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2007 | 1 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2007 | 5 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2007 | 6 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 5 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 15 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 11 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2007 | 21 | 0.070 |
Why?
|
| Child | 1 | 2007 | 197 | 0.060 |
Why?
|
| Adolescent | 1 | 2007 | 247 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 11 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 3 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 13 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2013 | 233 | 0.040 |
Why?
|
| Recurrence | 1 | 2015 | 8 | 0.030 |
Why?
|
| Schwann Cells | 1 | 2015 | 1 | 0.030 |
Why?
|
| Gels | 1 | 2015 | 2 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 4 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 16 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 19 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2015 | 7 | 0.030 |
Why?
|
| Collagen | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 12 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 25 | 0.030 |
Why?
|
| Materials Testing | 1 | 2015 | 26 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2014 | 1 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2014 | 3 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2014 | 8 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 8 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 39 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 50 | 0.030 |
Why?
|
| Rats | 1 | 2015 | 234 | 0.030 |
Why?
|
| HIV Long-Term Survivors | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vaginal Douching | 1 | 2014 | 1 | 0.030 |
Why?
|
| HIV | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2014 | 28 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 47 | 0.030 |
Why?
|
| Alleles | 1 | 2013 | 65 | 0.020 |
Why?
|
| Middle Aged | 1 | 2014 | 792 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 105 | 0.020 |
Why?
|
| Poly I-C | 1 | 2006 | 2 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 4 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 9 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 15 | 0.010 |
Why?
|